Point72 Asset Management L.P. Boosts Stock Holdings in Immunome, Inc. (NASDAQ:IMNM)

Point72 Asset Management L.P. grew its stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 22.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 470,647 shares of the company's stock after purchasing an additional 85,580 shares during the period. Point72 Asset Management L.P. owned about 0.78% of Immunome worth $6,881,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of IMNM. Marshall Wace LLP boosted its holdings in Immunome by 228.5% during the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company's stock worth $20,731,000 after purchasing an additional 1,191,774 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company's stock worth $50,971,000 after buying an additional 324,614 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Immunome by 217.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company's stock valued at $6,469,000 after acquiring an additional 302,916 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock worth $10,684,000 after purchasing an additional 237,497 shares during the period. Finally, AXA S.A. purchased a new position in Immunome in the second quarter valued at about $2,174,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IMNM has been the subject of a number of recent research reports. Wedbush reissued an "outperform" rating and issued a $33.00 target price on shares of Immunome in a research report on Friday, October 25th. Stephens assumed coverage on Immunome in a research note on Friday, November 8th. They issued an "overweight" rating and a $30.00 price objective on the stock. Finally, Piper Sandler cut their target price on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $28.83.

Immunome Stock Performance

NASDAQ IMNM traded up $0.99 during trading hours on Monday, hitting $14.72. The company had a trading volume of 527,069 shares, compared to its average volume of 779,719. The firm has a 50 day simple moving average of $12.23 and a 200 day simple moving average of $13.47. Immunome, Inc. has a 52 week low of $6.93 and a 52 week high of $30.96. The firm has a market capitalization of $918.82 million, a price-to-earnings ratio of -1.84 and a beta of 1.83.

Insider Activity

In other news, insider Robert Lechleider purchased 15,805 shares of the stock in a transaction on Thursday, November 21st. The shares were acquired at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the transaction, the insider now directly owns 15,805 shares of the company's stock, valued at approximately $149,831.40. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CTO Philip Tsai acquired 21,000 shares of the business's stock in a transaction dated Thursday, November 21st. The stock was purchased at an average price of $9.43 per share, with a total value of $198,030.00. Following the completion of the acquisition, the chief technology officer now directly owns 21,000 shares in the company, valued at approximately $198,030. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 102,862 shares of company stock worth $978,045. 8.60% of the stock is owned by company insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.